Avastin Market, By Indication (Metastatic colorectal cancer, Non-squamous non-small cell lung cancer, Recurrent glioblastoma, Metastatic renal cell carcinoma, Persistent cervical cancer, Recurrent cervical cancer, Metastatic cervical cancer, Stage III or

The Global Avastin Market is estimated to be valued at USD 1,348.8 Mn in 2025 and is expected to reach USD 812.9 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of -7% from 2025 to 2032. Avastin, a potent anti-angiogenic agent, inhibits the growth of blood vessels supplying tumors, thereby slowing tumor growth and metastasis. While the market has benefited from growing awareness of personalized medicine, advancements in cancer diagnostics, and the development of combination therapies, it is facing significant challenges. High treatment costs, side effects, and the emergence of biosimilars are limiting growth. Although ongoing research and expanding indications present opportunities, these factors are contributing to a decline in the Avastin market, with limited prospects for substantial growth in the coming years.

Market Dynamics

The global Avastin market, while influenced by several key factors, is experiencing a decline rather than growth. The rising incidence and prevalence of various types of cancer, along with the increasing demand for targeted therapies, have historically driven the market. Additionally, advancements in personalized medicine and companion diagnostics have helped identify patients who would benefit from Avastin. However, the high cost of Avastin therapy limits its accessibility, especially in low- and middle-income countries. The expiration of Avastin's patent has also led to the entry of biosimilars, further threatening the original drug’s market share. Despite these challenges, there are still opportunities for growth, such as expanding Avastin's indications to other cancers, developing combination therapies, and increasing adoption in emerging markets. However, ongoing competition from biosimilars, pricing pressures, and alternative therapies are contributing to a decrease in the overall market size, with limited prospects for significant growth in the coming years.

Key Features of the Study

• This report provides in-depth analysis of the global Avastin market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global Avastin market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Genentech (Part of Roche)
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global Avastin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Avastin market

Market Segmentation

• Indication Insights (Revenue, USD Mn, 2020 - 2032)
• Metastatic colorectal cancer
• Non-squamous non-small cell lung cancer
• Recurrent glioblastoma
• Metastatic renal cell carcinoma
• Persistent cervical cancer
• Recurrent cervical cancer
• Metastatic cervical cancer
• Stage III or IV epithelial ovarian cancer
• Stage III or IV fallopian tube cancer
• Stage III or IV primary peritoneal cancer
• Platinum-resistant recurrent epithelial ovarian cancer
• Platinum-resistant recurrent fallopian tube cancer
• Platinum-resistant recurrent primary peritoneal cancer
• Platinum-sensitive recurrent epithelial ovarian cancer
• Platinum-sensitive recurrent fallopian tube cancer
• Platinum-sensitive recurrent primary peritoneal cancer
• Hepatocellular carcinoma
• Dose Strength Insights (Revenue, USD Mn, 2020 - 2032)
• Vial (100 mg/4 mL)
• Vial (400 mg/16 mL)
• Sales Channel Insights (Revenue, USD Mn, 2020 - 2032)
• Online
• Offline
• Regional Insights (Revenue, USD Mn, 2020 - 2032)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• Genentech (Part of Roche)

Show more